Insta
Bharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)
In a boost for India's maiden indigenously developed COVID-19 vaccine, Brazilian health regulator Anvisa has given the nod to "exceptional import" of Hyderabad-based Bharat Biotech's Covaxin, reports Times of India.
It should be noted that as per a loosely translated version of Anvisa's announcement, the body has given the approval for an initial four million doses of Covaxin for distribution and use "under controlled" and specific conditions.
Upon the use of these four million doses, Anvisa will analyse the data to assess the further quantities of Covaxin to be imported.
It should be noted that back in March, Anvisa had turned down the first import request made by the Brazilian Health Ministry. After this, the Ministry approached Anvisa again in May. Bharat Biotech had also approached Anvisa in May end seeking approval for two Good Manufacturing Practices (GMP) implemented by it.
In this light, announcing the approval for Covaxin, Anvisa took note of the improvements made in the manufacturing line at Bharat Biotech's facility in India.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest